Selective targeting of neurons using nanomedicine-based strategies: open questions and new opportunities

Neuron-related disorders have a significant impact on our society. These disorders include a wide range of pathologies with neuronal disruption such as neurodegenerative diseases (e.g., Alzheimer’s and Parkinson’s) and metabolic diseases that are strictly regulated by neuronal connections (e.g., insulin resistance and obesity). However, investigation of the pathophysiology and pharmacological treatment of these disorders is limited due to the difficulty of targeting specific populations of neurons, low bioavailability in the brain and side effects of the drugs by off-target actions. To express their opinions on the recent progress of the nano-DDS targeting neurons, Dr. Sabina Quader (Senior Research Scientist, Innovation Center of NanoMedicine, Japan) has submitted an article together with Prof. Rosalia Rodriguez-Rodriguez (Associate Professor, Basic Sciences Department, Faculty of Medicine and Health Science, Universitat International de Catalunya, Spain) in Nanomedicine on-line on February 28, 2022.

https://www.futuremedicine.com/doi/10.2217/nnm-2021-0486

<Contact>

Makoto Shimazaki, Ph.D:  shimazaki-m@kawasaki-net.ne.jp

Misato Yamamoto:  yamamoto-m@kawasaki-net.ne.jp